SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-067790
Filing Date
2023-12-04
Accepted
2023-12-04 16:36:10
Documents
14
Period of Report
2023-11-29
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K abio-20231129.htm   iXBRL 8-K 44045
2 EX-10.1 abio-ex10_1.htm EX-10.1 24563
3 EX-10.2 abio-ex10_2.htm EX-10.2 24570
  Complete submission text file 0000950170-23-067790.txt   218505

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT abio-20231129.xsd EX-101.SCH 2484
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT abio-20231129_pre.xml EX-101.PRE 9853
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT abio-20231129_lab.xml EX-101.LAB 13352
8 EXTRACTED XBRL INSTANCE DOCUMENT abio-20231129_htm.xml XML 4679
Mailing Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021
Business Address 10170 CHURCH RANCH WAY SUITE 100 WESTMINSTER CO 80021 7209402200
ARCA biopharma, Inc. (Filer) CIK: 0000907654 (see all company filings)

IRS No.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-22873 | Film No.: 231463729
SIC: 2835 In Vitro & In Vivo Diagnostic Substances